Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Protagenic Therapeutics Inc (PTIXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.38 | 52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 |
52 Weeks Range 0.00 - 0.24 | Updated Date 05/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 491613 |
Shares Outstanding - | Shares Floating 491613 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Protagenic Therapeutics Inc
Company Overview
History and Background
Protagenic Therapeutics Inc. is a biotechnology company focused on developing novel therapeutics for neurological and neuropsychiatric disorders. Specific founding details and milestones are not readily available in common databases.
Core Business Areas
- Drug Discovery and Development: Focused on identifying and developing innovative therapeutic candidates for neurological and neuropsychiatric disorders.
- Peptide Therapeutics: Specializes in utilizing peptide-based approaches to target disease-specific mechanisms.
Leadership and Structure
Information regarding the specific leadership team and organizational structure is not readily accessible in common databases.
Top Products and Market Share
Key Offerings
- PT00114: Protagenic's lead therapeutic candidate (PT00114), targeting neuropsychiatric disorders. Market share data and revenue information is not publicly available. Competitors would include pharmaceutical companies that make treatments for neuropsychiatric disorders, such as Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high research and development costs, and regulatory hurdles. The market for neurological and neuropsychiatric drugs is substantial and growing due to increasing prevalence of these conditions.
Positioning
Protagenic Therapeutics aims to carve a niche within the neurological and neuropsychiatric market. Competitive advantage could potentially stem from peptide-based therapeutics.
Total Addressable Market (TAM)
The global market for neurological and neuropsychiatric disorders is estimated to be in the hundreds of billions of dollars. Protagenic's positioning within this TAM will depend on the success of its lead therapeutic candidate.
Upturn SWOT Analysis
Strengths
- Peptide-based therapeutic approach
- Novel therapeutic candidates
- Focus on neuropsychiatric disorders
Weaknesses
- Limited public information
- Dependence on lead therapeutic candidate
- High R&D costs inherent in biotech
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of therapeutic pipeline
- Successful clinical trials for PT00114
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Funding challenges
Competitors and Market Share
Key Competitors
- LLY
- PFE
- JNJ
Competitive Landscape
Protagenic faces intense competition from established pharmaceutical companies. Its competitive advantage lies in its novel peptide-based therapeutic approach, although concrete financial data of Protagenic does not exist.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends cannot be determined due to lack of available data.
Future Projections: Future growth projections are speculative and dependent on the success of its lead therapeutic candidate and are unavailable at this time
Recent Initiatives: Information on recent strategic initiatives is not widely available.
Summary
Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric disorders and utilizes peptide-based therapeutics. The company faces significant competition in the pharmaceutical industry and depends heavily on its lead drug. Due to limited publicly available data, it is difficult to assess the financial viability or predict the company's future performance. Success hinges on clinical trials, funding, and successfully navigating the regulatory landscape. The lack of information makes a comprehensive analysis difficult.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (if available)
- Company Website
- Industry Reports
- News Articles
Disclaimers:
The analysis is based on limited publicly available information. Market share data is estimated based on the overall market for neuropsychiatric disorder treatments and does not represent Protagenic Therapeutics' specific market share, as concrete revenue is not available. This analysis is for informational purposes only and does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-04-27 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.